Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00291226 · ClinicalTrials.gov registry record · Phase 2
Glycine vs Placebo for the Schizophrenia Prodrome
A Phase 2 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00291226 is a Phase 2 study that has completed, run by Yale University. The registered enrollment target is 8 participants.
The verdict
NCT00291226, a Phase 2 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
Interventions
- DRUG Placebo
- DRUG Glycine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2006-03 |
| Est. Completion | 2009-07 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00291226
The ClinicalTrials.gov registry entry for NCT00291226 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Yale University, which has 1,492 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00291226 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00291226 about?
NCT00291226 is a clinical study titled "Glycine vs Placebo for the Schizophrenia Prodrome". Glycine is a natural amino acid neurotransmitter that acts as a co-agonist at NMDA receptors in brain. We hypothesize that symptoms of the schizophrenia prodrome will improve with glycine to a greater degree than with placebo.
What is the current status of trial NCT00291226?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2006-03. Estimated completion is 2009-07.
What interventions are being tested in trial NCT00291226?
The interventions under investigation include: Placebo (DRUG), Glycine (DRUG).
Who is sponsoring clinical trial NCT00291226?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.